4D Molecular Therapeutics, Inc. – NASDAQ:FDMT

Add to watchlist

$6.52

+0.96

+17.48%

Market open

Closed in about 2 hours

-79.61%

month

-79.61%

quarter

-73.70%

year

Market Cap	272.05M
Enterprise value	472.01M

P/E	-5.08
EV/Sales	250.93
EV/EBITDA	-3.04
Price/Sales	270.19
Price/Book	2.19
PEG ratio	0.17
EPS	-2.5

Revenue	20.45M
EBITDA	-116.39M
Income	-104.55M
Revenue Q/Q	-90.60%
Revenue Y/Y	826.68%

Profit margin	-8608.08%
Oper. margin	-8763.96%
Gross margin	0%
EBIT margin	-8763.96%
EBITDA margin	-569.11%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Profit margin
Jun 2023	239K	-29.61M	-12391.63%
Sep 2023	20.20M	-10.25M	-50.76%
Dec 2023	-19K	-32.28M	169910.53%
Mar 2024	28K	-32.40M	-115717.86%

4D Molecular Therapeutics Financials Estimate

Q Y

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Analyst Estimates
Mar 2024	28K	-32.40M	-115717.86%
Sep 2025	500K	-35.21B	-7043412.06%
Oct 2025	500K	-49.76M	-9952.94%
Dec 2025	500K	-53.21M	-10642.75%

Analysts Price target
Financials & Ratios estimates

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Debt to assets
Jun 2023	352503000	725.29M	205.75%
Sep 2023	361613000	31.67M	8.76%
Dec 2023	339891000	32.06M	9.43%
Mar 2024	629884000	29.32M	4.66%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Cash Flow
Jun 2023	-22.06M	49.28M	130.51M
Sep 2023	-1.17M	29.98M	10.55M
Dec 2023	-24.65M	-6.68M	4.76M
Mar 2024	-29.08M	-263.25M	318.83M

4D Molecular Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

4D Molecular Therapeutics
Employees

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Employee count
Aug 2023	137
Sep 2023	137
Oct 2023	137
Nov 2023	137
Dec 2023	144
Jan 2024	144
Feb 2024	144
Mar 2024	147
Apr 2024	147
May 2024	147
Jun 2024	171
Jul 2024	171

4D Molecular Therapeutics
Hedge Funds Holdings Q3 2022

77.55% -3.30%

of FDMT is owned by hedge funds

81 -8

hedge funds hold FDMT stock

25.06M -993.41K

shares is hold by hedge funds

FDMT hedge funds holdings changes

4D Molecular Therapeutics
Insider Trading

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	614665
Feb 2024	0	104208
Mar 2024	0	7583
Apr 2024	0	9903
May 2024	0	1750
Jun 2024	0	14680
Jul 2024	0	20917
Aug 2024	0	500
Sep 2024	0	500

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	16 Sep 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right To Buy)	500	$6.49	$3,245
Option	16 Sep 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	500	$6.49	$3,245
Sale	16 Sep 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	500	$16.33	$8,165
Option	19 Aug 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right To Buy)	500	$6.49	$3,245
Option	19 Aug 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	500	$6.49	$3,245
Sale	19 Aug 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	500	$15	$7,500
Option	16 Jul 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right To Buy)	1,250	$8.04	$10,050
Option	16 Jul 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right To Buy)	500	$6.49	$3,245
Option	16 Jul 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	1,250	$8.04	$10,050
Option	16 Jul 2024	BIZILY SCOTT officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	500	$6.49	$3,245

FDMT insider trading transactions

4D Molecular Therapeutics
Executives

Insider	Age	Compensation
Dr. David H. Kirn (1963) Co-Founder, Chief Executive Officer, Pres & Director	62	$701,530
Mr. August J. Moretti Esq., J.D. (1951) Chief Financial Officer	74	$632,760
Dr. Robert S. Fishman (1962) Chief Medical Officer & Therapeutic Area Head of Pulmonology	63	$184,620
Dr. David E. Schaffer Ph.D. (1970) Co-Founder, Chief Scientific Advisor & Independent Director	55	$108,380
Dr. John F. Milligan (1961) Executive Chairman	64	$55,840

4D Molecular Therapeutics
Latest News

Wednesday, 13 November 2024
18:20	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
16:05	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones	globenewswire.com
Monday, 4 November 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation	accesswire.com
Sunday, 3 November 2024
11:00	Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations	accesswire.com
Saturday, 2 November 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out	accesswire.com
Sunday, 27 October 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations	accesswire.com
Saturday, 26 October 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out	accesswire.com
Sunday, 20 October 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part	accesswire.com
Saturday, 19 October 2024
11:00	Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations	accesswire.com
Friday, 18 October 2024
11:00	The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud	accesswire.com
Thursday, 17 October 2024
11:00	An Inquiry Has Been Launched Into 4D Molecular Therapeutics, Inc. For Securities Law Violations And Affected Shareholders Should Contact The Schall Law Firm	accesswire.com
Tuesday, 15 October 2024
11:00	4D Molecular Therapeutics, Inc. Is Being Looked Into For Securities Law Violations And Affected Shareholders Are Encouraged To Contact The Schall Law Firm	accesswire.com
Monday, 14 October 2024
11:00	The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud	accesswire.com
Sunday, 13 October 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations	accesswire.com
Saturday, 12 October 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out	accesswire.com
Friday, 11 October 2024
11:00	Shareholders Are Encouraged To Take Part In The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations	accesswire.com
Thursday, 10 October 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation	accesswire.com
Wednesday, 9 October 2024
11:00	Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations	accesswire.com
Tuesday, 8 October 2024
11:00	4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out	accesswire.com
Monday, 7 October 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Law Violations	accesswire.com
Sunday, 6 October 2024
11:00	4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out	accesswire.com
Saturday, 5 October 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Law Violations	accesswire.com
Friday, 4 October 2024
12:35	4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure	seekingalpha.com
11:00	4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out	accesswire.com
Thursday, 3 October 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions	accesswire.com
Wednesday, 2 October 2024
11:00	4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out	accesswire.com
Tuesday, 1 October 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions	accesswire.com
Monday, 30 September 2024
11:00	4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out	accesswire.com
Sunday, 29 September 2024
11:00	Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Law Violations	accesswire.com
Saturday, 28 September 2024
11:00	4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out	accesswire.com

Ideas & Opinions

Seeking Alpha 29 Apr 2024

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Seeking Alpha 11 Feb 2024

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Seeking Alpha 6 Feb 2024

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Seeking Alpha 25 Jan 2024

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Seeking Alpha 25 Sep 2023

4D Molecular Therapeutics: Some Failures, A Few Key Successes
Seeking Alpha 10 Jul 2023

4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance
Seeking Alpha 7 Jul 2023

4D Molecular Therapeutics: A Complicated Story
Seeking Alpha 25 Mar 2023

4D Molecular Therapeutics: Promising Preliminary Safety And Efficacy For 4D-310
Seeking Alpha 3 Jan 2023

4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
Seeking Alpha 31 Aug 2022

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Frequently Asked Questions (FAQ)

What's the price of 4D Molecular Therapeutics stock today?

One share of 4D Molecular Therapeutics stock can currently be purchased for approximately $6.52.
When is 4D Molecular Therapeutics's next earnings date?

Unfortunately, 4D Molecular Therapeutics's (FDMT) next earnings date is currently unknown.
Does 4D Molecular Therapeutics pay dividends?

No, 4D Molecular Therapeutics does not pay dividends.
How much money does 4D Molecular Therapeutics make?

4D Molecular Therapeutics has a market capitalization of 272.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 562.29% to 20.72M US dollars.
What is 4D Molecular Therapeutics's stock symbol?

4D Molecular Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FDMT".
What is 4D Molecular Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of 4D Molecular Therapeutics?

Shares of 4D Molecular Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are 4D Molecular Therapeutics's key executives?
4D Molecular Therapeutics's management team includes the following people:
- Dr. David H. Kirn Co-Founder, Chief Executive Officer, Pres & Director(age: 62, pay: $701,530)
- Mr. August J. Moretti Esq., J.D. Chief Financial Officer(age: 74, pay: $632,760)
- Dr. Robert S. Fishman Chief Medical Officer & Therapeutic Area Head of Pulmonology(age: 63, pay: $184,620)
- Dr. David E. Schaffer Ph.D. Co-Founder, Chief Scientific Advisor & Independent Director(age: 55, pay: $108,380)
- Dr. John F. Milligan Executive Chairman(age: 64, pay: $55,840)
Is 4D Molecular Therapeutics founder-led company?

Yes, 4D Molecular Therapeutics is a company led by its founders Dr. David H. Kirn and Dr. David E. Schaffer Ph.D..
How many employees does 4D Molecular Therapeutics have?

As Jul 2024, 4D Molecular Therapeutics employs 171 workers, which is 16% more then previous quarter.
When 4D Molecular Therapeutics went public?

4D Molecular Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 11 Dec 2020.
What is 4D Molecular Therapeutics's official website?

The official website for 4D Molecular Therapeutics is 4dmoleculartherapeutics.com.
Where are 4D Molecular Therapeutics's headquarters?

4D Molecular Therapeutics is headquartered at 5858 Horton Street, EmeryVille, CA.
How can i contact 4D Molecular Therapeutics?

4D Molecular Therapeutics's mailing address is 5858 Horton Street, EmeryVille, CA and company can be reached via phone at +51 05052680.

4D Molecular Therapeutics, Inc.

4dmoleculartherapeutics.com

Exchange:

NASDAQ

Full time employees:

147

Industry:

Biotechnology

Sector:

Healthcare

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

+51 05052680

5858 Horton Street
EmeryVille, CA 94608

CIK: 0001650648
ISIN: US35104E1001
CUSIP: 35104E100